Cytokinetics, Incorporated
Cytokinetics, Incorporated (Nasdaq: CYTK) is a biopharmaceutical company that discovers, develops and commercializes small-molecule medicines targeting muscle function for cardiovascular and neuromuscular diseases. Its first commercial product, MYQORZO (aficamten), is an oral cardiac myosin inhibitor approved in the… From the company’s description.
In fiscal 2025, Cytokinetics, Incorporated reported revenue of $88.04M, up 376.6% from fiscal 2024, and a net loss of $784.96M. Its operating margin was −695.4%, and operations used $510.01M in cash. Over the twelve months to Jun 30, 2026, revenue was $67.67M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cytokinetics, Incorporated does
In the company’s own words
Cytokinetics, Incorporated (Nasdaq: CYTK) is a biopharmaceutical company that discovers, develops and commercializes small-molecule medicines targeting muscle function for cardiovascular and neuromuscular diseases. Its first commercial product, MYQORZO (aficamten), is an oral cardiac myosin inhibitor approved in the United States, European Union and China for adults with symptomatic obstructive hypertrophic cardiomyopathy; customers include patients and the specialist cardiologists who diagnose and treat the condition. The company is also developing aficamten for non-obstructive HCM, omecamtiv mecarbil, a cardiac myosin activator for heart failure with reduced ejection fraction, ulacamten for a subset of patients with heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy and other conditions involving impaired muscle function. Cytokinetics operates as an integrated specialty biopharmaceutical business, combining research and development with commercialization; it uses licensing partners for aficamten in China and Japan and relies on third parties for manufacturing. In 2025, it received FDA approval for MYQORZO and began U.S. commercial sales in early 2026. Its website is www.cytokinetics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1061983
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cytokinetics, Incorporated — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cytokinetics, Incorporated’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Cytokinetics, Incorporated’s bonds, as funds hold them
Funds report holding 2 issues of Cytokinetics, Incorporated’s debt, $117.89M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.87%, maturing 2027 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cytokinetics, Incorporated and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cytokinetics, Incorporated's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cytokinetics, Incorporated's last four quarterly filings that the numbers alone won't show?”